Transgene Biotek, a Biotechnology firm has received patent in the US for its novel drug to be developed for treatment of Hepato-cellular cancer (HCC) the most common liver cancer.
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. Hepatocellular carcinoma is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected.
"This granting of a USA patent is a significant step in moving ahead with the development of this novel drug," Transgene Biotek said in a filing to the BSE (Bombay Stock Exchange). The company's novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.
The company's current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.
Subscribe to PharmaTutor News Alerts by Email >>
